Radioactive drug takes aim at Hard-to-Treat tumors

NCT ID NCT07165132

Recruiting now Disease control Sponsor: RayzeBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The drug delivers a powerful radioactive particle directly to cancer cells. The study aims to find the safest dose and see if it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RYZ401 (a radioactive drug containing Actinium-225)
What this could lead to: If it works, this could point toward a new treatment option for people with neuroendocrine tumors that are hard to treat.
What could go wrong: This is a very early Phase 1 trial with only 104 participants, so it may not work or could have unexpected side effects. The radioactive drug may cause damage to healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenoma, Islet Cell carcinoid tumor digestive system neuroendocrine neoplasm digestive system neuroendocrine tumor, grade 1/2 meningioma neoplasm neuroendocrine neoplasm pancreatic neuroendocrine tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOID CARCINOID TUMOR GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE GEP-NET NEUROENDOCRINE TUMORS PANCREATIC NET SOLID TUMOR SOMATOSTATIN RECEPTOR

Contacts and locations

Locations

Research Facility
RECRUITING

Iowa City, Iowa, 52242, United States
Research Facility
RECRUITING

Lexington, Kentucky, 40536, United States
Research Facility
RECRUITING

St Louis, Missouri, 63104, United States
Research Facility
RECRUITING

St Louis, Missouri, 63110, United States
Research Facility
RECRUITING

Columbus, Ohio, 43210, United States
Research Facility
RECRUITING

Nashville, Tennessee, 37232, United States
Research Facility
RECRUITING

Salt Lake City, Utah, 84112, United States
Research Facility
RECRUITING

Toronto, Ontario, M5G 2C4, Canada
Research Facility
RECRUITING

Montreal, Quebec, H3T 1E2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.